The National Institutes of Health's (NIH) “All of Us” research project was spotlighted for its potential to explain racial disparities due to coronavirus disease 2019 (COVID-19); the FDA has told Cool Clouds Distribution to stop selling its fruite-flavored e-cigarettes (e-cigs); the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) partner to promote minority participation in cancer treatment trials.
Reported by Kaiser Health News, the National Institutes of Health’s (NIH) “All of Us” research project was spotlighted for being the world’s most diverse health database and for its potential ability to assist in explaining racial disparities due to coronavirus disease 2019 (COVID-19). Started in 2018, the database has collected blood and DNA samples, as well as electronic health records, from more than 270,000 individuals, over half of whom are minorities. This information is now being leveraged by the NIH to examine antibody test results of at least 10,000 program volunteers, as well as to examine the influence of social determinants of health on potential future pandemics.
Yesterday, the FDA sent a letter to the manufacturer behind Puff Bar e-cigarettes to stop distribution and remove all of their fruity, disposable e-cigs from the market within 15 business days. Reported by The Associated Press, the move now targets disposable e-cigarettes, which antivaping advocates pointed out as a potential loophole in February when the FDA primarily targeted reusable vaping devices, like Juul. Cool Clouds Distribution, the company behind Puff Bar, issued a notice on its website that all online sales and distribution have ceased until further notice.
Announced today, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) have partnered to promote the participation of racial and minority populations in cancer treatment trials. The joint initiative was indicated as a call to action to members of the cancer community, who have been asked to submit novel strategies and practical solutions to increase cancer treatment trial participation and address challenges that inhibit participation, such as provider bias. Strategies and ideas that are submitted may be modified, combined, and implemented through organizational mechanisms, such as the ASCO Targeted Agent and Profiling Utilization Registry study.
Streamlined Referral Intervention Sees Great Success Among Patients With Head/Neck Cancer
October 17th 2023A 2022 yearlong initiative at Summa Health Cancer Institute saw 100% of its patients with head and neck cancer undergoing radiation treatment referred to an oncology dietician for nutritional support and/or speech and swallow therapy.
Read More
Oncology Financial Navigator Ensures Vital Care Access, Eases Economic Burden
October 13th 2023According to the National Cancer Institute, in the year following a cancer diagnosis, the average cost of medical care plus medication exceeds $42,000, with some treatments having a price tag of more than $1 million.
Read More
Mobile Mammography Unit Increases Breast Cancer Screening Among Latina Patients
October 7th 2023Pinky, a mobile mammography unit from Stony Brook University Hospital Cancer Center on Long Island, increased screening for breast cancer from 9% to 69% among the predominantly Latina population that it serves.
Read More
Dempsey Center Research Demonstrates Importance of Supporting Oncology Care Providers
October 6th 2023The interrelated concepts of burnout, secondary traumatic stress, moral distress, compassion fatigue, and compassion satisfaction have been identified as having a profound impact on the quality of life of health care providers.
Read More
Sustainable Cancer Screening Has Potential, With the Right Tools
October 6th 2023A presentation at the Association of Community Cancer Centers’ 40th National Oncology Conference explored how a cancer screening initiative can be sustainable and revenue positive while driving value-based savings in an evolving market.
Read More